Søgeresultater - Alan Nicholas

  • Showing 1 - 7 results of 7
Refine Results
  1. 1
    Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial

    Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial af Daneng Li, Han Chong Toh, Philippe Merle, Kaoru Tsuchiya, Sairy Hernandez, Wendy Verret, Alan Nicholas, Masatoshi Kudo

    Udgivet 2022
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  2. 2
    Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study

    Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a Phase II Study af Nancy U. Lin, Mark D. Pegram, Solmaz Sahebjam, Nuhad K. Ibrahim, Anita Fung, Anna Cheng, Alan Nicholas, Whitney P. Kirschbrown, Priya Kumthekar

    Udgivet 2021
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  3. 3
    Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150

    Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150 af Richard S. Finn, Peter R. Galle, Michel Ducreux, Ann‐Lii Cheng, Norelle R. Reilly, Alan Nicholas, Sairy Hernandez, Ning Ma, Philippe Merle, Riad Salem, Daneng Li, В. В. Бредер

    Udgivet 2024
    Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  4. 4
    Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM)

    Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM) af Herbert I. Hurwitz, Benjamin Tan, James A. Reeves, Henry Xiong, Brad Somer, Heinz‐Josef Lenz, Howard S. Höchster, Frank A. Scappaticci, John F. Palma, Richard Price, John J. Lee, Alan Nicholas, Nicolas Sommer, Johanna C. Bendell

    Udgivet 2018
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  5. 5
    Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

    Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma af Ann‐Lii Cheng, Shukui Qin, Masafumi Ikeda, Peter R. Galle, Michel Ducreux, Tae‐You Kim, Ho Yeong Lim, Masatoshi Kudo, В. В. Бредер, Philippe Merle, Ahmed O. Kaseb, Daneng Li, Wendy Verret, Ning Ma, Alan Nicholas, Yifan Wang, Lindong Li, Andrew X. Zhu, Richard S. Finn

    Udgivet 2021
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  6. 6
    Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non–small cell lung cancer

    Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant thera... af Valerie W. Rusch, Alan Nicholas, G. Alexander Patterson, Salama N. Waqar, Eric M. Toloza, Eric B. Haura, Dan J. Raz, Karen L. Reckamp, Robert E. Merritt, Dwight H. Owen, David J. Finley, Ciaran McNamee, Justin D. Blasberg, Edward B. Garon, John D. Mitchell, Robert C. Doebele, Frank A. Baciewicz, Misako Nagasaka, Harvey I. Pass, Katja Schulze, Ann Johnson, Paul A. Bunn, Bruce E. Johnson, Mark G. Kris, David J. Kwiatkowski, Ignacio I. Wistuba, Jamie E. Chaft, David P. Carbone, Jay M. Lee

    Udgivet 2022
    Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:
  7. 7
    Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial

    Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial af Jamie E. Chaft, Filiz Öezkan, Mark G. Kris, Paul A. Bunn, Ignacio I. Wistuba, David J. Kwiatkowski, Dwight H. Owen, Yan Tang, Bruce E. Johnson, Jay M. Lee, Gerard Lozanski, Maciej Pietrzak, Michał Seweryn, Woo Yul Byun, Katja Schulze, Alan Nicholas, Ann Johnson, Jessica M. Grindheim, Stephanie Hilz, David S. Shames, Chris Rivard, Eric M. Toloza, Eric B. Haura, Ciaran McNamee, G. Alexander Patterson, Saiama N. Waqar, Valerie W. Rusch, David P. Carbone, Saiama N. Waqar, Elaine Shum, Misako Nagasaka, Marianna Koczywas, Edward B. Garon, David J. Finley, David Ross Camidge, Jennifer W. Carlisle, Justin D. Blasberg

    Udgivet 2022
    Få fuldtekst Få fuldtekst
    Artigo
    Føj til favoritter
    Saved in:

Søgeredskaber: